Xiangya Cardiopulmonary Health and Disease Cohort

I1 Inclusion and exclusion criteria for retrospective cohorts 1) Inclusion criteria: 1. Patients were either treated or hospitalized in the physical examination center, outpatient and emergency clinic in the Xiangya Hospital of Central South University from January 2010 to April 2025. 2. Completion of cardiac function (e.g., echocardiography) and pulmonary function (e.g., pulmonary function test) assessment, with an interval of no more than 1 year between the two. 3. Those who had complete clinical diagnostic and therapeutic information (e.g., medical history, medication records, laboratory test results, imaging reports) except for the cardiopulmonary function test report. 2)Exclusion criteria 1. Patients with complete loss of cardiopulmonary function test reports or key data (e.g., VO2peak, FEV1/FVC, LVEF). 2. Patients with loss of key clinical diagnostic and treatment data (e.g., medical history, medication records, laboratory test results). 2.1.2 Inclusion and exclusion criteria for prospective cohort 1）Inclusion criteria 1. Patients who have been included in the retrospective cohort. 2. Voluntarily signed informed consent form to participate in long-term follow-up for ≥3 years. 3. Able to complete the baseline assessment of the prospective cohort (including cardiopulmonary function retesting, questionnaires, etc.). 4. Stable conditions for follow-up (e.g., living in the local area, available valid contact information, no plans to move in the short term or go out for a long period of time). 2\) Exclusion Criteria. 1. Patients who have been excluded from the retrospective cohort or for whom key data are missing. 2. With severe cognitive impairment, psychiatric disease or verbal communication disorder, unable to cooperate with follow-up and data collection. 3. Expected survival time \<3 years (e.g., advanced malignancy, end-stage cardiopulmonary failure, etc.). 4. Incomplete cardiopulmonary function or other clinical data during the baseline assessment. 5. Those who plan to participate in other interventional clinical trials that may interfere with the assessment of cardiopulmonary function.